What the Research Says About Psilocybin

Microdosing is where personal experience and lab results sit furthest apart, which makes it one of the most interesting questions in the field. Many people describe steadier mood, better focus, and more creativity. Surveys say much the same: in one analysis of 278 people's own accounts, mostly from people who microdosed LSD, improved mood and focus were the benefits mentioned most, though some also reported physical discomfort or more anxiety.

Researchers have started testing it with placebos. In a large study where 191 people ran their own blinded protocol, most of them using LSD, both the real-thing group and the placebo group improved over four weeks on several measures, and the study found no significant difference between them. In a placebo-controlled study of 34 healthy people, a small dose of dried mushrooms produced measurable effects, including a change in one brain-wave measure, but no clear shift in mood or creativity on the days tested. The effects were clearest in people who correctly guessed what they had taken, about three quarters could tell, and a few thinking tests showed small changes in the other direction.

So the honest answer today is that nobody knows yet how much of what people report comes from the mushroom itself, how much from the intention and routine around it, and how much from the two working together. Those are not rivals. Expectation and routine are a real part of any practice. The studies so far were short and mostly in healthy volunteers or people who chose to microdose, and longer work in the people most likely to try it is what is needed next.

Most of the clinical trials above, on depression, smoking, and headache, used psilocybin on its own, made in a lab. A mushroom is not that. It holds psilocybin alongside several close relatives and a great deal of other natural material. One of the microdosing studies did use whole dried mushrooms, but it compared them with a placebo, not with isolated psilocybin. We have not found a human trial that compares the whole mushroom with the isolated version directly. A few registered trials are now testing whole mushrooms, for conditions such as PTSD and OCD, but none of them makes that comparison either. Our clinical trials page lists them.

There is one early hint. In a 2024 study in mice, an extract of the whole mushroom changed proteins involved in connection between brain cells more than pure psilocybin given at the same amount, and the difference was still there at the second check, eleven days later. The immediate effects looked similar.

Everyone in the studies above was screened by clinicians and supported through the experience. That is very different from trying something on your own, and it is part of why the results look the way they do.

• Psychosis or bipolar disorder. A personal or family history is a standard reason to be excluded from trials, and a reason to talk with a doctor first.
• Pregnancy and nursing. There is not enough safety research to say anything reassuring.
• Heart conditions and blood pressure. Trials report temporary rises in blood pressure and heart rate.
• Medications. Some medications can change how these mushrooms affect you or add risk. The research shows it for antidepressants (SSRIs and SNRIs), which can blunt the effects, and for lithium, where seizures have been reported. Interactions with most other medications have not been studied. Never stop a prescription on your own. Talk to your doctor or pharmacist.

If you ever do explore this, the common advice in the research community is to start low, go slowly, and not do it alone the first time.